Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 519

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults

Open access
Wen, Patrick Y., van den Bent, Martin, Youssef, Gilbert, Cloughesy, Timothy F., Ellingson, Benjamin M., Weller, Michael, Galanis, Evanthia, Barboriak, Daniel P., de Groot, John, Gilbert, Mark R., Huang, Raymond, Lassman, Andrew B., Mehta, Minesh, Molinaro, Annette M., Preusser, Matthias, Rahman, Rifaquat, Shankar, Lalitha K., Stupp, Roger, Villanueva-Meyer, Javier E., Wick, Wolfgang, Macdonald, David R., Reardon, David A., Vogelbaum, Michael A., Chang, Susan M.·2023·Journal of Clinical Oncology

Abstract

PURPOSE: The Response Assessment in Neuro-Oncology (RANO) criteria for high-grade gliomas (RANO-HGG) and low-grade gliomas (RANO-LGG) were developed to improve reliability of response assessment in glioma trials. Over time, some limitations of these criteria were identified, and challenges emerged regarding integrating features of the modified RANO (mRANO) or the immunotherapy RANO (iRANO) criteria. METHODS: Informed by data from studies evaluating the different criteria, updates to the RANO criteria are proposed (RANO 2.0). RESULTS: We recommend a standard set of criteria for both high- and low-grade gliomas, to be used for all trials regardless of the treatment modalities being evaluated. In the newly diagnosed setting, the postradiotherapy magnetic resonance imaging (MRI), rather than the postsurgical MRI, will be used as the baseline for comparison with subsequent scans. Since the incidence of pseudoprogression is high in the 12 weeks after radiotherapy, continuation of treatment and confirmation of progression during this period with a repeat MRI, or histopathologic evidence of unequivocal recurrent tumor, are required to define tumor progression. However, confirmation scans are not mandatory after this period nor for the evaluation of treatment for recurrent tumors. For treatments with a high likelihood of pseudoprogression, mandatory confirmation of progression with a repeat MRI is highly recommended. The primary measurement remains the maximum cross-sectional area of tumor (two-dimensional) but volumetric measurements are an option. For IDH wild-type glioblastoma, the nonenhancing disease will no longer be evaluated except when assessing response to antiangiogenic agents. In IDH-mutated tumors with a significant nonenhancing component, clinical trials may require evaluating both the enhancing and nonenhancing tumor components for response assessment. CONCLUSION: The revised RANO 2.0 criteria refine response assessment in gliomas.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.23.01059

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

Metadata

Authors
Wen, P. Y., van den Bent, M., Youssef, G., Cloughesy, T. F., Ellingson, B. M., Weller, M., Galanis, E., Barboriak, D. P., de Groot, J., Gilbert, M. R., Huang, R., Lassman, A. B., Mehta, M., Molinaro, A. M., Preusser, M., Rahman, R., Shankar, L. K., Stupp, R., Villanueva-Meyer, J. E., Wick, W., Macdonald, D. R., Reardon, D. A., Vogelbaum, M. A., & Chang, S. M.
Venue
Journal of Clinical Oncology
Published
2023-11-20
Volume
41
Issue
33
Pages
5187-5199
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W4387163062
Cited by
519
References
40
FWCI
73.65
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. https://app.cochat.ai/papers/10.1200/jco.23.01059
The paper
Wen, P. Y., van den Bent, M., Youssef, G., Cloughesy, T. F., Ellingson, B. M., Weller, M., Galanis, E., Barboriak, D. P., de Groot, J., Gilbert, M. R., Huang, R., Lassman, A. B., Mehta, M., Molinaro, A. M., Preusser, M., Rahman, R., Shankar, L. K., Stupp, R., Villanueva-Meyer, J. E., . . . Chang, S. M. (2023). RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.01059

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.